These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21289271)

  • 21. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for the prevention and treatment of type 1 diabetes.
    Goudy KS; Tisch R
    Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
    Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
    Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity.
    Chatenoud L
    Curr Opin Organ Transplant; 2009 Aug; 14(4):351-6. PubMed ID: 19610168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of insulin-dependent diabetes mellitus.
    Masteller EL; Bluestone JA
    Curr Opin Immunol; 2002 Oct; 14(5):652-9. PubMed ID: 12183168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
    Chatenoud L; Thervet E; Primo J; Bach JF
    Proc Natl Acad Sci U S A; 1994 Jan; 91(1):123-7. PubMed ID: 8278351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD3-specific antibodies: a portal to the treatment of autoimmunity.
    Chatenoud L; Bluestone JA
    Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance.
    Chatenoud L; Bach JF
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S73-81. PubMed ID: 16187942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics.
    You S; Chatenoud L
    Methods Mol Biol; 2016; 1371():117-42. PubMed ID: 26530798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.
    Mignogna C; Maddaloni E; D'Onofrio L; Buzzetti R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1209-1219. PubMed ID: 34936848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.
    von Herrath MG; Coon B; Wolfe T; Chatenoud L
    J Immunol; 2002 Jan; 168(2):933-41. PubMed ID: 11777992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures.
    Kuhn C; Besançon A; Lemoine S; You S; Marquet C; Candon S; Chatenoud L
    J Autoimmun; 2016 Jul; 71():69-77. PubMed ID: 27216249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes.
    Ke Q; Kroger CJ; Clark M; Tisch RM
    Front Immunol; 2020; 11():624568. PubMed ID: 33679717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD3 mAbs for treatment of type 1 diabetes.
    Kaufman A; Herold KC
    Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes.
    Zhang L; Sosinowski T; Cox AR; Cepeda JR; Sekhar NS; Hartig SM; Miao D; Yu L; Pietropaolo M; Davidson HW
    J Autoimmun; 2019 Jan; 96():50-58. PubMed ID: 30122420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [One step towards restoration of self-tolerance in human autoimmune diseases].
    Chatenoud L
    Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of monoclonal antibodies to restore self-tolerance in established autoimmunity.
    Chatenoud L
    Endocrinol Metab Clin North Am; 2002 Jun; 31(2):457-75, ix. PubMed ID: 12092461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-antigenic and antigenic interventions in type 1 diabetes.
    Rydén AK; Wesley JD; Coppieters KT; Von Herrath MG
    Hum Vaccin Immunother; 2014; 10(4):838-46. PubMed ID: 24165565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review on Monoclonal Antibodies (mAbs) as a Therapeutic Approach for Type 1 Diabetes.
    Agarwal G; Patel M
    Curr Diabetes Rev; 2024; 20(7):e310823220578. PubMed ID: 37653635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
    Kuhn C; Weiner HL
    Immunotherapy; 2016 Jul; 8(8):889-906. PubMed ID: 27161438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.